Registration number:
Axxora (UK) Limited
for the Year Ended 31 July 2023
Axxora (UK) Limited
(Registration number: 03033257)
Contents
Company Information |
|
Balance Sheet |
|
Notes to the Financial Statements |
Axxora (UK) Limited
(Registration number: 03033257)
Company Information
Director |
K A Cannon |
Registered office |
|
Auditors |
|
Axxora (UK) Limited
(Registration number: 03033257)
Balance Sheet as at 31 July 2023
Note |
2023 |
2022 |
|
Fixed assets |
|||
Investments |
|
|
|
Current assets |
|||
Debtors |
|
|
|
Creditors: Amounts falling due within one year |
( |
( |
|
Net current liabilities |
( |
( |
|
Net liabilities |
( |
( |
|
Capital and reserves |
|||
Called up share capital |
|
|
|
Share premium reserve |
|
|
|
Profit and loss account |
( |
( |
|
Total equity |
( |
( |
These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.
Approved and authorised by the
......................................... |
Axxora (UK) Limited
(Registration number: 03033257)
Notes to the Financial Statements for the Year Ended 31 July 2023
General information |
The company is a private company limited by share capital, incorporated in England & Wales.
The address of its registered office is:
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Group accounts not prepared
Going concern
The company has made a loss during the year ended 31 July 2023 and has net current liabilities and net liabilities. The directors are confident that the company can trade profitably in the future.
The company has received confirmation of continued support from its parent company Enzo Life Sciences Overseas Holding Co. Inc.& the ultimate controlling party Enzo Bicochem Inc.
Audit report
Axxora (UK) Limited
(Registration number: 03033257)
Notes to the Financial Statements for the Year Ended 31 July 2023
Foreign currency transactions and balances
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.
Business combinations
Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.
Investments
Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Staff numbers |
The average number of persons employed by the company (including the director) during the year, was
Interest payable and similar charges |
Interest payables includes £176,155 (2022 - £85,930) payable on loans from group companies.
Loss before tax |
Arrived at after charging/(crediting)
2023 |
2022 |
|
Foreign exchange gains/losses |
(1,911) |
4,631 |
Axxora (UK) Limited
(Registration number: 03033257)
Notes to the Financial Statements for the Year Ended 31 July 2023
Investments |
2023 |
2022 |
|
Investments in subsidiaries |
|
|
Subsidiaries |
£ |
Cost or valuation |
|
At 1 August 2022 |
|
At 31 July 2023 |
|
Carrying amount |
|
At 31 July 2023 |
|
At 31 July 2022 |
|
Debtors |
2023 |
2022 |
|
Amounts owed by group undertakings and undertakings in which the company has a participating interest |
|
|
Total current trade and other debtors |
|
|
Creditors |
2023 |
2022 |
|
Due within one year |
||
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
|
|
Contingent assets |
The company has an unprovided deferred tax asset in respect of tax losses available to be set off against future taxable profits. This asset is valued at £235,145 (2022: £191,584) and is calculated using a tax rate of 25% (2022: 25%). Deferred tax balances are not discounted.
Related party transactions |
The company has taken advantage of the exemptions in FRS 102 Section 1A "Related Party Disclosures" from disclosing transactions with other members of the group and key management personnel.
Axxora (UK) Limited
(Registration number: 03033257)
Notes to the Financial Statements for the Year Ended 31 July 2023
Parent and ultimate parent undertaking |
The parent company is Enzo Life Sciences Overseas Holding Co, Inc. a company incorporated in the United States of America.
The company is ultimately controlled by Enzo Biochem Inc.,a company listed on the New York Stock Exchange.
Copies of the accounts are available from:
Investor and Public Relations
LifeSci Advisors
250 West 55th Street Suite 3401
New York
NY